Transforming Promise Into Patient Impact

We are on a mission to deliver targeted therapies that treat rare forms of cancer.

Sierra is currently awaiting topline results for its pivotal Phase 3 clinical study, MOMENTUM, a randomized double-blind trial for myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.

Sierra is awaiting topline results for its pivotal Phase 3 clinical study, MOMENTUM, a randomized double-blind trial for myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.

Recent News